Systematically sequencing the genome and studying the function of genes from viruses will enable the development of phage-gene libraries that can in turn enable the faster development of genetic tools for advancing molecular biology.
Do you have ideas that could inform an ambitious project that FESI has a comparative advantage pursuing? We want to hear it.
Friends of FESI have identified priority use cases to inform project ideas.
Good data is a critical component of delivering effective government services from local to federal levels. But now, too much useful data lives in a silo.
Interagency Community Investment Committee agencies should partner with the Small Business Administration to use their existing authority and infrastructure to pilot a secondary market for their securitized debt instruments.
The space economy is enormous, but one of its biggest challenges is tiny: space debris.
The CHIPS and Science Act establishes a compelling vision for U.S. innovation and place-based industrial policy, but that vision is already being hampered by tight funding.
The U.S. would need 65,000 miles of pipeline to achieve net-zero emissions by 2050. Here’s how the Biden Administration can expanding the use of low-emission, composite materials to support a net-zero vision.
Research and engineering to reverse antibiotic resistance in aquatic bacteria, through the application of a well-validated CRISPR-based genetic system, can help catalyze safer, more sustainable land-based aquaculture as a nutritious and affordable food source.
Humanity needs catalysts to create fuel, feedstocks to make materials, and fertilizers to grow food. Catalysts allow us to arrange atoms into the molecules we need with extremely high selectivity, cleanliness, and low energy input.
RNA therapeutics are gaining popularity since they are cheap and easy to make, but sequencing technologies today rely on converting RNA back to cDNA, which collapses information on the more than 150 different chemically modified bases for RNA into just four bases.
Many antibodies that scientists purchase from commercial manufacturers to conduct their research do not work as advertised, because most have never been validated properly.